Medicines containing pallivizumab as the active substance
Liek s účinnou látkou palivizumab
Slovakia · Banská Bystrica · how to bid here →
Your path to submission
- Deadline: 5 October at 08:00 — 2 days left.
- You submit on ÚVO / EVO — not here and not by e-mail. ↗
- Offer and evidence in: SLK, CES.
- Collect your evidence — the eligibility requirements are listed above; for many of them the analysis explains how to obtain them.
Clement What the numbers say about this buyer
- 10% of this buyer's awards went to companies that had already won here before (61 awards since 2018, spread over 5 companies). That is well below the sector norm (63%) — this buyer switches suppliers more often than others.n = 61 awards since 2018
- In this sector the buyer awards roughly every 3 months (10 awards, most recently September 2026) — the next award is due around December 2026 by that rhythm. The last award went to PHOENIX Zdravotnícke zásobovanie, a.s..n = 10
- 22% of the bids received came from small and medium-sized enterprises (11 procedures with a bid mix). Sector: 72%.n = 11
- 26% of awards went to companies from abroad (61 awards with a known winner country). Sector average: 12%.n = 61
- The award came in at a median 102% of the estimated value (8 awards with both estimate and value) — pricing at the estimate is usually about right here. Sector: 91%.n = 8
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 27/09/2026.
Foreign bidders
In Slovakia · Medical equipment & pharma, 17 contracts went to foreign companies over the last 3 years (of 1,850 recorded awards).
Typical field: median 1 (from 10 awards).
What the buyer is looking for
The subject-matter of the contract is: The active substance in palivizumab Palivizumab is a recombinant humanised monoclonal antibody produced by DNA technology in mouse myeloma host cells. One 0.5 ml vial contains 50 mg palivizumab The product is indicated for the prevention of severe lower respiratory tract disease requiring hospitalisation, caused by respiratory syncytial virus (RSV) in children at high risk of RSV: • children who were born at the 35th week of gestation or earlier and are under 6 months of age at the beginning of the RSV season; • children under 2 years of age who require treatment for bronchopulmonary dysplasia in the last 6 months; • children under 2 years of age with hemodynamically significant congenital heart disease
Selection criteria — in the procurement documents
The buyer states in the notice that the selection criteria are in the procurement documents (link on the right), not in the EU form. The document analysis below extracts them from there — bid and evidence in Slovak, Czech.
Contract
Who has won here before
| Company | Awards | Period |
|---|---|---|
| MED - ART, spol. s r.o. | 6 | 2025 |
| PHOENIX Zdravotnícke zásobovanie, a.s. | 2 | 2024–2026 |
| ELMED, s.r.o. | 1 | 2025 |
| Pragolab s.r.o. | 1 | 2024 |
| BLUEMED s.r.o. | 1 | 2024 |
How often this buyer tenders this
Who knows the rhythm prepares instead of reacting.